(Q43280713)

18 November 2017

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting (English)

1 reference

18 November 2017

1 reference

1 reference

1 reference

T Mittendorf

1

1 reference

18 November 2017

J Smith-Palmer

2

1 reference

18 November 2017

L Timlin

3

1 reference

18 November 2017

M Happich

4

1 reference

18 November 2017

G Goodall

5

1 reference

18 November 2017

3 September 2009

1 reference

Diabetes, Obesity and Metabolism

18 November 2017

1 reference

18 November 2017

11

1 reference

18 November 2017

11

1 reference

18 November 2017

1068-1079

1 reference

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

18 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2009.01099.X

Crossref

reference URL

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2009.01099.X

Crossref

reference URL

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2009.01099.X

Crossref

reference URL

10.1111/J.1463-1326.2009.01099.X

21 January 2018

Identifiers

DOI

1 reference

18 November 2017

1 reference